Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 595,300 shares, a growth of 13.6% from the December 15th total of 523,900 shares. Based on an average daily volume of 260,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 7.5% of the shares of the company are sold short.

Institutional Investors Weigh In On Citius Pharmaceuticals

Large investors have recently bought and sold shares of the company. Chelsea Counsel Co. raised its position in shares of Citius Pharmaceuticals by 9.8% in the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock valued at $141,000 after buying an additional 25,000 shares in the last quarter. Virtu Financial LLC bought a new position in Citius Pharmaceuticals in the third quarter valued at approximately $50,000. Geode Capital Management LLC raised its position in Citius Pharmaceuticals by 14.1% during the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after purchasing an additional 232,656 shares in the last quarter. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the third quarter worth $47,000. Finally, Miller Investment Management LP lifted its stake in Citius Pharmaceuticals by 99.3% during the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the last quarter. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CTXR shares. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Stock Up 1.2 %

Shares of CTXR traded up $0.04 during trading hours on Friday, hitting $3.30. 78,395 shares of the company were exchanged, compared to its average volume of 177,269. Citius Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $26.75. The company has a market cap of $25.51 million, a price-to-earnings ratio of -0.55 and a beta of 1.30. The firm’s fifty day moving average is $4.09 and its 200 day moving average is $10.92.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.